{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:48:12Z","timestamp":1780073292068,"version":"3.54.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,2]]},"DOI":"10.7759\/cureus.74970","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T14:31:23Z","timestamp":1733149883000},"source":"Crossref","is-referenced-by-count":6,"title":["Advancements in the Treatment of Multiple Myeloma"],"prefix":"10.7759","author":[{"given":"Esteban","family":"Zavaleta-Monestel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Quesada-Villase\u00f1or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monserrat","family":"Barrantes-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Arguedas-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeimy","family":"Campos-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Rojas-Chinchilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Garc\u00eda-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josu\u00e9","family":"Castro-Ulloa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Anch\u00eda-Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ricardo","family":"Montenegro-Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Valor social de la mejora del abordaje del mieloma m\u00faltiple en el Sistema Nacional de Salud. (2019). https.\/\/weber.org.es\/publicacion\/valor-social-de-la-mejora-del-abordaje-del-mieloma-multiple-en-el-sistema-nacional-d...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.32776\/revbiomed.v17i3.459","article-title":"Historia del mieloma m\u00faltiple. [Article in Spanish]","volume":"17","author":"D\u00edaz-Maqueo JC","year":"2006","unstructured":"D\u00edaz-Maqueo JC. Historia del mieloma m\u00faltiple. [Article in Spanish]. Rev Biom\u00e9d. 2006, 17:225-9. 10.32776\/revbiomed.v17i3.459","journal-title":"Rev Biom\u00e9d"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1157\/13107365","article-title":"Multiple myeloma. [Article in Spanish]","volume":"129","author":"Garc\u00eda-Sanz R","year":"2007","unstructured":"Garc\u00eda-Sanz R, Mateos MV, Miguel JF. Multiple myeloma. [Article in Spanish]. Med Clin (Barc). 2007, 129:104-15. 10.1157\/13107365","journal-title":"Med Clin (Barc)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar SV","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024, 99:1802-24. 10.1002\/ajh.27422","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar SK","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, et al.. Multiple myeloma. Nat Rev Dis Primers. 2017, 3:10.1038\/nrdp.2017.46","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","unstructured":"Key statistics about multiple myeloma. (2024). https.\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/about\/key-statistics.html."},{"key":"ref7","unstructured":"Epidemiolog\u00eda del mieloma m\u00faltiple. (2024). http.\/\/contraelcancer.es\/es\/todo-sobre-cancer\/tipos-cancer\/mieloma-multiple\/epidemiolog\u00eda."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00733-2","article-title":"I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients","volume":"12","author":"Gill SK","year":"2022","unstructured":"Gill SK, Unawane R, Wang S, et al.. I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients. Blood Cancer J. 2022, 12:10.1038\/s41408-022-00733-2","journal-title":"Blood Cancer J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872009000400015","article-title":"La gen\u00e9tica como factor pron\u00f3stico y terap\u00e9utico en el mieloma m\u00faltiple. [Article in Spanish]","volume":"137","author":"Conte G","year":"2009","unstructured":"Conte G, Braggio E, Figueroa G, Fonseca R. La gen\u00e9tica como factor pron\u00f3stico y terap\u00e9utico en el mieloma m\u00faltiple. [Article in Spanish]. Rev M\u00e9dica Chile. 2009, 137:552-8. 10.4067\/S0034-98872009000400015","journal-title":"Rev M\u00e9dica Chile"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022, 97:1086-107. 10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"ref11","article-title":"Utilidad de pruebas de laboratorio en el diagn\u00f3stico de mieloma m\u00faltiple. [Article in Spanish]","volume":"62","author":"V\u00e1zquez AP","year":"2015","unstructured":"V\u00e1zquez AP, Palma AZ. Utilidad de pruebas de laboratorio en el diagn\u00f3stico de mieloma m\u00faltiple. [Article in Spanish]. Rev Latinoam Patol Clin Med Lab. 2015, 62:55-62.","journal-title":"Rev Latinoam Patol Clin Med Lab"},{"key":"ref12","unstructured":"Etapas del mieloma m\u00faltiple. (2018). https.\/\/www.cancer.org\/es\/cancer\/tipos\/mieloma-multiple\/deteccion-diagnostico-clasificacion-por-etapas\/tasas-de-super...."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1979.tb01124.x","article-title":"Clinical staging in multiple myeloma","volume":"42","author":"Woodruff RK","year":"1979","unstructured":"Woodruff RK, Wadsworth J, Malpas JS, Tobias JS. Clinical staging in multiple myeloma. Br J Haematol. 1979, 42:199-205. 10.1111\/j.1365-2141.1979.tb01124.x","journal-title":"Br J Haematol"},{"key":"ref14","unstructured":"FDA aprueba un nuevo uso para la lenalidomida en mieloma m\u00faltiple. (2017). https.\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2017\/fda-lenalidomida-mieloma-mantenimiento."},{"key":"ref15","unstructured":"Talidomida (Thalomid\u00ae). informaci\u00f3n \u00fatil para los pacientes y sus familiares. (2010). https:\/\/gepac.es\/multimedia\/gepac2016\/pdf\/GU%C3%8DA_TALIDOMIDA.pdf."},{"key":"ref16","unstructured":"La FDA aprueba una indicaci\u00f3n m\u00e1s amplia para carfilzomib en pacientes con mieloma m\u00faltiple. (2015). https.\/\/www.cancer.gov\/espanol\/noticias\/temas-y-relatos-blog\/2015\/carfilzomib-mieloma."},{"key":"ref17","unstructured":"Bendamustina. (2021). https.\/\/www.grupolinfomas.com\/wp-content\/uploads\/2021\/05\/bendamustina.pdf."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701694194","article-title":"Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma","volume":"48","author":"Fenk R","year":"2007","unstructured":"Fenk R, Michael M, Zohren F, et al.. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma. 2007, 48:2345-51. 10.1080\/10428190701694194","journal-title":"Leuk Lymphoma"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos M","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, et al.. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007, 357:2123-32. 10.1056\/NEJMoa070594","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy MQ","year":"2011","unstructured":"Lacy MQ, Allred JB, Gertz MA, et al.. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011, 118:2970-5. 10.1182\/blood-2011-04-348896","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi ED","year":"2008","unstructured":"Hsi ED, Steinle R, Balasa B, et al.. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008, 14:2775-84. 10.1158\/1078-0432.CCR-07-4246","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi K","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, et al.. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011, 377:813-22. 10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"key":"ref23","unstructured":"XXIV Congreso Argentino de Farmacia Hospitalaria. (2024). https.\/\/aafh.org.ar\/."},{"key":"ref24","unstructured":"Dexametasona. corticosteroides. (2024). https:\/\/accessmedicina.mhmedical.com\/content.aspx?bookid=1552&sectionid=90369286#."},{"key":"ref25","article-title":"Bortezomib as an alternative in the treatment of patients with malignant gammopathy. [Article in Spanish]","volume":"32","author":"Guzm\u00e1n DL","year":"2008","unstructured":"Guzm\u00e1n DL, Vera CF, Penella MM, Lara MM, Vidal VJ, Sirvent MM. Bortezomib as an alternative in the treatment of patients with malignant gammopathy. [Article in Spanish]. Farm Hosp. 2008, 32:280-5.","journal-title":"Farm Hosp"},{"key":"ref26","unstructured":"Informe de Posicionamiento Terap\u00e9utico de carfilzomib (Kyprolis\u00ae)\r\nen combinaci\u00f3n con daratumumab y dexametasona (esquema\r\nDaraKd) para pacientes con Mieloma M\u00faltiple en Reca\u00edda y\/o\r\nRefractario. (2022). https.\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2022\/IPT_57-2022-Kyprolis.pdf."},{"key":"ref27","unstructured":"Anexo I. ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2010\/2010052679008\/anx_79008_es.pdf."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar SV","year":"2011","unstructured":"Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011, 8:479-91. 10.1038\/nrclinonc.2011.63","journal-title":"Nat Rev Clin Oncol"},{"key":"ref29","unstructured":"Terapia con medicamentos para el mieloma m\u00faltiple. (2024). https.\/\/www.cancer.org\/es\/cancer\/tipos\/mieloma-multiple\/tratamiento\/quimioterapia.html."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2013.10.012","article-title":"New drugs in the treatment of multiple myeloma. [Article in Spanish]","volume":"143","author":"Oriol A","year":"2014","unstructured":"Oriol A, Motll\u00f3 C. New drugs in the treatment of multiple myeloma. [Article in Spanish]. Med Clin (Barc). 2014, 143:268-74. 10.1016\/j.medcli.2013.10.012","journal-title":"Med Clin (Barc)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11072087","article-title":"Breaking through multiple myeloma: a paradigm for a comprehensive tumor ecosystem targeting","volume":"11","author":"Solimando AG","year":"2023","unstructured":"Solimando AG, Krebs M, Desantis V, et al.. Breaking through multiple myeloma: a paradigm for a comprehensive tumor ecosystem targeting. Biomedicines. 2023, 11:10.3390\/biomedicines11072087","journal-title":"Biomedicines"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2008.14.S7-A.12","article-title":"Current and emerging treatments for multiple myeloma","volume":"14","author":"Schwartz RN","year":"2008","unstructured":"Schwartz RN, Vozniak M. Current and emerging treatments for multiple myeloma. J Manag Care Pharm. 2008, 14:12-9. 10.18553\/jmcp.2008.14.S7-A.12","journal-title":"J Manag Care Pharm"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13840","article-title":"Treatment horizon in multiple myeloma","volume":"109","author":"Soekojo CY","year":"2022","unstructured":"Soekojo CY, Chng WJ. Treatment horizon in multiple myeloma. Eur J Haematol. 2022, 109:425-40. 10.1111\/ejh.13840","journal-title":"Eur J Haematol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab afodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria V","year":"2024","unstructured":"Hungria V, Robak P, Hus M, et al.. Belantamab afodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024, 391:393-407. 10.1056\/NEJMoa2405090","journal-title":"N Engl J Med"},{"key":"ref35","unstructured":"Tratamiento del mieloma. https.\/\/www.aeal.es\/mieloma-multiple-espana\/7-tratamiento-del-mieloma\/."},{"key":"ref36","unstructured":"Opciones de tratamiento de primera l\u00ednea. https.\/\/myeloma.org.br\/es\/opciones-de-tratamiento-de-primera-linea\/."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau P","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, et al..  Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016, 374:1621-34. 10.1056\/NEJMoa1516282","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart AK","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, et al.. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015, 372:142-52. 10.1056\/NEJMoa1411321","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo A","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, et al.. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016, 375:754-66. 10.1056\/NEJMoa1606038","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos MV","year":"2019","unstructured":"Mateos MV, Blacklock H, Schjesvold F, et al.. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019, 6:459-69. 10.1016\/S2352-3026(19)30110-3","journal-title":"Lancet Haematol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02757-0","article-title":"Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan","volume":"111","author":"Kubo K","year":"2020","unstructured":"Kubo K, Hori M, Ohta K, et al.. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. Int J Hematol. 2020, 111:65-74. 10.1007\/s12185-019-02757-0","journal-title":"Int J Hematol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero P","year":"2021","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021, 100:10.1016\/j.ctrv.2021.102284","journal-title":"Cancer Treat Rev"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30323-9","article-title":"Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study","volume":"7","author":"Tacchetti P","year":"2020","unstructured":"Tacchetti P, Pantani L, Patriarca F, et al.. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol. 2020, 7:861-73. 10.1016\/S2352-3026(20)30323-9","journal-title":"Lancet Haematol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol L","year":"2019","unstructured":"Rosi\u00f1ol L, Oriol A, Rios R, et al.. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019, 134:1337-45. 10.1182\/blood.2019000241","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala SA","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, et al.. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021, 9:10.3390\/medsci9010003","journal-title":"Med Sci (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/316755-advancements-in-the-treatment-of-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T14:31:31Z","timestamp":1733149891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/316755-advancements-in-the-treatment-of-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.74970","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,2]]}}}